# Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

> **NCT04013854** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 67 (actual)

## Conditions studied

- Melanoma Stage III
- Melanoma

## Interventions

- **DRUG:** nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04013854
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-01
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04013854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04013854, "Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04013854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*